Blar i Institutt for klinisk og molekylær medisin på tidsskrift "Cell Death & Disease"
Viser treff 1-5 av 5
-
JWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells
(Journal article; Peer reviewed, 2014)Gastric cancer is the third most common malignancy in China, with a median 5-year survival of only 20%. Cisplatin has been used in first-line cancer treatment for several types of cancer including gastric cancer. However, ... -
Parp3 promotes astrocytic differentiation through a tight regulation of Nox4-induced ROS and mTorc2 activation
(Peer reviewed; Journal article, 2020)Parp3 is a member of the Poly(ADP-ribose) polymerase (Parp) family that has been characterized for its functions in strand break repair, chromosomal rearrangements, mitotic segregation and tumor aggressiveness. Yet its ... -
PML regulates neuroprotective innate immunity and neuroblast commitment in a hypoxic–ischemic encephalopathy model
(Journal article; Peer reviewed, 2016) -
Sensing soluble uric acid by Naip1-Nlrp3 platform
(Peer reviewed; Journal article, 2021)Uric acid (UA), a product of purine nucleotide degradation able to initiate an immune response, represents a breakpoint in the evolutionary history of humans, when uricase, the enzyme required for UA cleavage, was lost. ... -
TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer
(Journal article; Peer reviewed, 2014)Cisplatin is a cytotoxic platinum compound that triggers DNA crosslinking induced cell death, and is one of the reference drugs used in the treatment of several types of human cancers including gastric cancer. However, ...